TMBIM1 Antibody

What is TMBIM1 and why is it a significant research target?

TMBIM1 (Transmembrane BAX Inhibitor Motif-containing Protein 1), also known as Protein lifeguard 3 (LFG3) or Protein RECS1 homolog, is a protein involved in crucial cellular processes including apoptosis regulation and stress response. TMBIM1 has gained research significance due to:

• Its role in negatively regulating aortic matrix metalloproteinase-9 (MMP9) production, potentially offering protection in vascular remodeling

• Its upregulation in various cancer types, particularly glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC)

• Its emerging role in cardiac protection during sepsis-induced cardiac dysfunction

Research into TMBIM1 antibodies allows for detection, quantification, and characterization of this protein in various experimental and clinical contexts, contributing to our understanding of disease mechanisms and potential therapeutic interventions.

What applications are TMBIM1 antibodies validated for?

TMBIM1 antibodies have been validated for several key applications, each with specific methodological considerations:

When selecting an antibody, researchers should consider the specific epitope targeted (N-terminal vs. C-terminal) as this may affect detection in different experimental contexts .

How should I optimize TMBIM1 antibody use for Western blotting?

For optimal Western blot results with TMBIM1 antibodies:

• Sample preparation: Use RIPA buffer containing PMSF and protease inhibitor cocktail for cell lysis. Maintain samples on ice for 30 minutes during lysis .

• Protein quantification: Determine protein concentration using the BCA method to ensure equal loading .

• Gel separation: TMBIM1 has a predicted molecular weight of 35 kDa; use 10-12% SDS-PAGE gels for optimal separation .

• Transfer conditions: Standard PVDF membranes with 5% skim milk blocking for 1 hour at room temperature .

• Antibody dilution: Primary antibody dilutions typically range from 1:500-1:2000 depending on the specific antibody. Incubate overnight at 4°C with gentle shaking .

• Detection: Both chemiluminescence and fluorescence-based detection systems work well, with quantification possible using software such as ImageJ .

• Controls: Include positive controls like RT4 cells which demonstrate reliable TMBIM1 expression .

How can I effectively use TMBIM1 antibodies to study its role in cancer progression?

Recent research has revealed significant roles for TMBIM1 in cancer biology, particularly in glioblastoma and pancreatic cancer. For investigating TMBIM1 in cancer progression:

• Expression analysis across cancer types:

  • Compare TMBIM1 expression across cancer vs. normal tissues using IHC with standardized scoring systems (0=negative, 1=low positive, 2=positive, 3=high positive)

  • Researchers have demonstrated that TMBIM1 is significantly upregulated in GBM tissues compared to non-tumor tissues

• Functional studies:

  • Combine TMBIM1 knockdown/overexpression with proliferation assays (CCK-8) and colony formation assays

  • Monitor cell cycle progression and apoptosis through flow cytometry after modulating TMBIM1 expression

  • Establish stable cell lines with modified TMBIM1 expression using lentiviral vectors and puromycin selection (2 μg/ml)

• Pathway analysis:

  • Examine relationships between TMBIM1 and signaling pathways like p38/MAPK in GBM or YBX1 in pancreatic cancer

  • Use co-immunoprecipitation to identify TMBIM1 interaction partners, such as demonstrated with Parkin in cardiac cells or YBX1 in pancreatic cancer

• In vivo tumor models:

  • Intracranial xenograft models using TMBIM1-knockdown cells have shown prolonged survival compared to controls

  • Monitor tumor growth parameters and survival time as demonstrated in PDAC mouse models

What strategies should I employ when studying TMBIM1's immunomodulatory functions?

TMBIM1 has recently been implicated in immune evasion mechanisms, particularly in pancreatic cancer. For investigating its immunomodulatory roles:

• Analysis of immune cell infiltration:

  • Use flow cytometry to analyze MDSC (CD11B+CD33+) recruitment in response to TMBIM1 expression

  • Compare immune cell populations in TMBIM1-high vs. TMBIM1-low tumors

• Cytokine/chemokine profiling:

  • Measure CCL2 and PD-L1 expression levels in relation to TMBIM1 using qPCR and ELISA

  • Conduct chemotaxis assays using conditioned media from TMBIM1-overexpressing cells to assess immune cell recruitment

• Mechanism of immune modulation:

  • Investigate TMBIM1's interaction with transcription factors like YBX1 through chromatin immunoprecipitation (ChIP) to determine effects on immune-related gene promoters

  • Examine how TMBIM1 expression affects responsiveness to immune checkpoint inhibitors in animal models

• Therapeutic targeting:

  • Combine TMBIM1 knockdown with anti-PD-1 antibody treatment in mouse models

  • Evaluate tumor size, weight, and immune infiltration in combination therapy vs. monotherapy groups

How do I address inconsistent TMBIM1 antibody staining patterns in tissue samples?

Researchers sometimes encounter variability in TMBIM1 immunostaining. To troubleshoot and optimize:

• Epitope accessibility issues:

  • TMBIM1 is a transmembrane protein with multiple membrane-spanning domains. Different antibodies target different epitopes (N-terminal vs. C-terminal)

  • For formaldehyde-fixed tissues, ensure adequate antigen retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Expression variability across tissues:

  • Create a systematic approach using tissue microarrays with known TMBIM1 expression

  • Include positive controls (e.g., colon tissue has shown strong cytoplasmic positivity)

• Antibody validation strategies:

  • Confirm specificity using TMBIM1 knockdown/overexpression samples

  • When possible, validate findings with at least two different antibodies targeting distinct epitopes

  • Compare staining patterns with gene expression data from the same samples

• Optimized protocols:

  • For IHC-P, use dilutions between 1:100-1:300 with overnight incubation at 4°C

  • Include blocking steps for endogenous peroxidase (3% H2O2 for 10 min) and serum blocking (1 hour)

  • Consider automated staining platforms to improve consistency across samples

What controls should I include when studying TMBIM1 in cell culture models?

A robust experimental design for TMBIM1 studies should include these key controls:

• Expression controls:

  • Positive control cell lines: RT4 cells have confirmed TMBIM1 expression

  • GBM cell lines (U87 and U251) express high levels of TMBIM1

  • Include normal human astrocytes as a comparative baseline for brain cancer studies

• Knockdown/overexpression validation:

  • Validate TMBIM1 knockdown efficiency using shRNA sequences (e.g., 5'-GATCCGGAGAGAGCGGTGAGTGATAGCTCGAGCTATCACTCACCGCTCTCTCCTTTTTTG-3')

  • Confirm knockdown/overexpression by both Western blot and qRT-PCR

• Functional assay controls:

  • Include cell cycle analysis in parallel with proliferation studies

  • For apoptosis studies, include both early (Annexin V) and late (cleaved caspase-3) markers

  • When studying drug sensitivity (e.g., TMZ in GBM), include dose-response curves with established sensitive cell lines

• Pathway investigation controls:

  • Include p38/MAPK pathway inhibitors or activators when studying TMBIM1's role in this pathway

  • For YBX1 interaction studies, include YBX1 knockdown conditions

How should I design experiments to investigate TMBIM1's role in drug resistance?

Research has implicated TMBIM1 in therapy resistance, particularly in GBM. For investigating this role:

• Cell line selection and preparation:

  • Use paired sensitive/resistant cell lines

  • Establish stable TMBIM1 knockdown and overexpression lines

  • Include isogenic cell lines that differ only in TMBIM1 expression

• Drug sensitivity testing:

  • For GBM studies, use temozolomide (TMZ) at clinically relevant concentrations

  • For pancreatic cancer, consider investigating gemcitabine sensitivity

  • Perform both short-term viability assays (72h) and long-term clonogenic survival assays

• Mechanism investigation:

  • Assess apoptotic markers (BAX, Bad, cleaved-Caspase3, Bcl-2) in relation to TMBIM1 expression

  • Evaluate p38 MAPK pathway activation (phospho-p38) in drug-treated cells

  • Examine cell cycle distribution before and after drug treatment

• In vivo resistance models:

  • Develop xenograft models with TMBIM1-modified tumors

  • Implement drug treatment schedules that mimic clinical protocols

  • Monitor not only tumor volume but also molecular markers of resistance

• Combination therapy approaches:

  • Test TMBIM1 targeting in combination with standard therapies

  • For immunotherapy resistance, combine TMBIM1 knockdown with checkpoint inhibitors

What methodological approaches should I use to study TMBIM1 in relation to immune checkpoint therapy?

Recent findings have connected TMBIM1 to immune checkpoint therapy resistance. To investigate this relationship:

• In vitro models:

  • Co-culture systems with tumor cells and immune cells (T cells, MDSCs)

  • Measure PD-L1 expression in relation to TMBIM1 levels through western blot and flow cytometry

  • Assess T cell activation markers and cytokine production in co-culture systems

• In vivo experimental design:

  • Generate syngeneic mouse models using cell lines with TMBIM1 knockdown

  • Administer anti-PD-1 antibody treatment (3 times/week via intraperitoneal injection)

  • Include four experimental groups: control, anti-PD-1 only, TMBIM1-knockdown only, and combination

• Outcome measurements:

  • Primary: tumor volume and weight measurements

  • Secondary: immune cell infiltration analysis via flow cytometry

  • Exploratory: transcriptome analysis of tumors across treatment groups

• Mechanistic investigations:

  • Examine CCL2 production and MDSC recruitment in relation to TMBIM1/YBX1 axis

  • Analyze nuclear translocation of YBX1 in response to TMBIM1 expression

  • Perform ChIP assays to confirm YBX1 binding to CCL2 and PD-L1 promoters

How can I resolve cross-reactivity issues when using TMBIM1 antibodies?

Cross-reactivity can complicate TMBIM1 detection. To address this issue:

• Antibody selection guidelines:

  • Choose antibodies with validated specificity for your species of interest

  • Consider the homology between species (e.g., human TMBIM1 shows 92% homology with cow, 86% with dog)

  • When possible, use monoclonal antibodies for highest specificity

• Validation strategies:

  • Perform parallel experiments with two antibodies targeting different TMBIM1 epitopes

  • Include TMBIM1 knockdown/knockout samples as negative controls

  • Consider pre-absorption tests with the immunizing peptide

• Optimization approaches:

  • Titrate antibody concentrations to minimize background while maintaining specific signal

  • Optimize blocking conditions (5% BSA may reduce non-specific binding compared to milk for some applications)

  • For Western blots, use longer washing steps and consider more stringent washing buffers

• Alternative detection methods:

  • When antibody specificity is questionable, confirm key findings with non-antibody methods

  • Consider mRNA detection (qRT-PCR, RNA-seq) as complementary approaches

  • For protein interaction studies, consider proximity ligation assays for higher specificity

What are the best approaches to quantify TMBIM1 expression in complex tissue samples?

Accurate quantification of TMBIM1 in heterogeneous samples requires careful methodology:

• IHC quantification strategies:

  • Use standardized scoring systems (0-3 scale) as implemented in GBM and PDAC studies

  • Consider automated image analysis software for unbiased quantification

  • Account for subcellular localization (primarily cytoplasmic for TMBIM1)

• Western blot quantification:

  • Normalize TMBIM1 signal to multiple housekeeping proteins (GAPDH, β-actin)

  • Use standard curves with recombinant TMBIM1 for absolute quantification

  • Apply ImageJ or similar software for densitometric analysis

• Single-cell approaches:

  • For heterogeneous tissues, consider single-cell RNA sequencing to identify cell-specific expression patterns

  • Use multiplexed immunofluorescence to correlate TMBIM1 with cell-type markers

• Mass spectrometry approaches:

  • For absolute quantification, develop targeted proteomics assays (MRM/PRM)

  • Consider using AQUA peptides as internal standards for TMBIM1 quantification

  • Implement protein extraction protocols optimized for membrane proteins

How do I differentiate between TMBIM family members when using antibodies?

The TMBIM protein family shares structural similarities, requiring careful antibody selection and validation:

• Family member characteristics:

  • TMBIM family includes TMBIM1-6, all containing the BAX inhibitor motif

  • Members share structural similarities but have distinct tissue expression patterns and functions

  • TMBIM1 has a predicted molecular weight of 35 kDa, which may differ from other family members

• Antibody selection criteria:

  • Choose antibodies raised against unique regions with minimal sequence homology to other TMBIM proteins

  • N-terminal targeted antibodies may offer better discrimination between family members

  • Review the immunogen sequence information provided by manufacturers

• Validation approaches:

  • Test antibody specificity against recombinant proteins of multiple TMBIM family members

  • Include overexpression controls for each family member to confirm specificity

  • Consider peptide competition assays with immunizing peptides

• Alternative approaches:

  • Use targeted gene expression assays (qRT-PCR with validated primers)

  • Consider using tagged constructs for overexpression studies to avoid antibody cross-reactivity issues

  • Implement gene editing technologies to specifically tag endogenous TMBIM1

How can TMBIM1 antibodies be used to study its emerging role in immune evasion mechanisms?

Recent research has unveiled TMBIM1's role in immune evasion, particularly in pancreatic cancer:

• Key research findings:

  • TMBIM1 interacts with YBX1, enhancing its binding to CCL2 and PD-L1 promoters

  • This interaction increases MDSC recruitment and creates an immunosuppressive microenvironment

  • High TMBIM1 expression correlates with resistance to immune checkpoint blockade therapy

• Antibody-based methodological approaches:

  • Use co-immunoprecipitation with TMBIM1 antibodies to identify binding partners

  • Perform ChIP assays to analyze YBX1 binding to target gene promoters

  • Implement proximity ligation assays to confirm TMBIM1-YBX1 interaction in situ

• Translational research applications:

  • Develop IHC protocols to detect TMBIM1/YBX1/PD-L1 co-expression in patient samples

  • Correlate TMBIM1 expression with immune cell infiltration patterns

  • Investigate TMBIM1 as a predictive biomarker for immunotherapy response

• Experimental models:

  • Generate mouse models with conditional TMBIM1 knockout in specific cell populations

  • Develop humanized mouse models to study TMBIM1's impact on human immune cell function

  • Create reporter systems to monitor CCL2 and PD-L1 expression in relation to TMBIM1

What are the current challenges in developing therapeutic strategies targeting TMBIM1?

As TMBIM1 emerges as a potential therapeutic target, several challenges need addressing:

• Target validation considerations:

  • Confirm TMBIM1's role across multiple cancer types beyond GBM and PDAC

  • Determine if TMBIM1 functions are tissue/context-specific

  • Evaluate potential on-target toxicities given TMBIM1's protective role in cardiac tissue

• Therapeutic approaches:

  • Small molecule inhibitors: Target TMBIM1-protein interactions (e.g., TMBIM1-YBX1)

  • RNAi-based approaches: Develop delivery systems for TMBIM1-targeting siRNAs

  • Combination strategies: TMBIM1 inhibition with checkpoint inhibitors may enhance efficacy

• Biomarker development:

  • Establish reliable IHC protocols for TMBIM1 detection in FFPE samples

  • Develop companion diagnostics to identify patients likely to benefit from TMBIM1-targeting

  • Correlate TMBIM1 expression with pathway activation markers (p-p38, YBX1 nuclear localization)

• Future research directions:

  • Structural studies to identify druggable pockets in TMBIM1

  • Development of functional antibodies that can modulate TMBIM1 activity

  • Investigation of TMBIM1's role in additional pathological contexts beyond cancer

How should researchers interpret conflicting data regarding TMBIM1's role in different disease contexts?

TMBIM1 exhibits context-dependent functions that require careful interpretation:

• Conflicting observations:

  • Protective role in cardiac tissue during sepsis vs. pathological role in cancer progression

  • Pro-survival functions in cancer cells vs. potential regulatory roles in normal tissues

  • Differential effects on p38 MAPK signaling depending on cellular context

• Methodological considerations:

  • Cell-type specific effects: Use cell-type specific markers when analyzing heterogeneous samples

  • Temporal dynamics: Consider acute vs. chronic effects of TMBIM1 manipulation

  • Dose-dependent effects: Evaluate TMBIM1 function across a range of expression levels

• Integrative analysis approaches:

  • Combine transcriptomic, proteomic, and functional data to build comprehensive models

  • Consider signaling network analysis rather than linear pathway evaluation

  • Implement mathematical modeling to account for feedback mechanisms

• Experimental design recommendations:

  • Include multiple cell types and tissue contexts in parallel experiments

  • Design time-course studies to capture dynamic effects

  • Use conditional and inducible systems to control TMBIM1 expression with temporal precision